Low-molecular-weight heparins (LMWHs) are poly-pharmacologic drugs used to treat thrombotic and cardiovascular disorders. Recently, several generic versions of branded LMWHs have been introduced. Although generic versions of LMWHs exhibit similar profiles, marked differences in their biological and pharmacologic properties have been demonstrated. Several studies have demonstrated differences in terms of anti-Xa activity and tissue factor pathway inhibitor release. The current data emphasize the need to consider multiple functional parameters when defining bioequivalence of biologic drugs and also underscore the importance of further pharmacologic studies involving animal and human clinical trials. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are currently developing guidelines for the acceptance of complex biological drugs including LMWHs. The US FDA considers these drugs as follow-on agents whereas the EMEA classifies these drugs as biosimilar agents. Until clear guidelines are developed, generic interchange of LMWHs may not be feasible.
Hirsh J., Raschke R.Heparin and low-molecular-weight heparin. Chest. 2004;126:188S-203S.
2.
Alban S.Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost . 2001;27: 503-511.
3.
Holmer E., Kurachi K., Soderstrom G.The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981;193:395-400.
4.
Khorana AA, Sahni A., Altland OD, Francis CWHeparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003;23:2110-2115.
5.
Bray B., Lane DA, Freyssinet JM, Pejler G., Lindahl U.Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J. 1989;262:225-232.
6.
Jeske WP, Walenga JM, Fareed J.Differentiating between the low molecular-weight heparins used for venous thromboembolism treatment and prophylaxis. Thromb Clin. IN PRESS.
7.
Casu B., Torri G.Structural characterization of low molecular weight heparins. Semin Thromb Hemost. 1999;25(suppl 3):17-25.
8.
Walenga JM, Petitou M., Samama M., Fareed J., Choay J.Importance of a 3-O-sulfate in a heparin pentasaccharide for antithrombotic activity. Thromb Res. 1988;52:553-563.
9.
Becker RCNew thrombolytic, anticoagulants and platelet antagonists: the future of clinical practice. J Thromb Thrombolysis. 1999;7:195-220.
10.
Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
11.
Cohen M., Demers C., Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med . 1997;337:447-452.
12.
2003P-0064: Withhold approval of generic Lovenox (enoxaparin sodium injection). Available at: http:// www.fda.gov/ohrms/dockets/DOCKETS/03p0064/ 03p0064.htm.
13.
Criteria, and evidence to assess actual or potential bioequivalence problems. Volume 21 CFR 320. 33: Federal Registrar; 1998.
14.
Samama MM, Gerotziafas GTComparative pharmacokinetics of LMWHs. Semin Thromb Hemost . 2000;26(suppl 1):31-38.
Lindahl U., Bäckström G., Thunberg L., Leder IGEvidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci. 1980 ;77:6551-6555.
17.
Petitou M., Lormeau JC, Choay J.Interaction of heparin and antithrombin III. The role of O-sulfate groups . Eur J Biochem.1988;176:637-640.
18.
Nugent MAHeparin sequencing brings structure to the function of complex oligosaccharides . Proc Natl Acad Sci. 2000;97:10301-10303.
19.
Jeske WP, Neville B., Ma Q., Hoppensteadt DA, Fareed J.Effect of 1,6-anhdro bicyclic ring structure on the pharmacokinetic and pharmacodynamic behavior of low molecular weight heparin. Blood. 2004;104:Abstract 1868.
20.
Jeske WP, Walenga JM, Ackerman PD, et al. Assay dependent variations in the anticoagulant and protamine sulfate neutralization profiles of generic copies of enoxaparin. Blood. 2006;108:272a.
21.
Fareed J., Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations . Semin Thromb Hemost. 2004;30: 703-713.
22.
Leong WL, Hoppensteadt D.Generic forms of low molecular weight heparins: some practical considerations . Clin Appl Thromb Hemost. 2003;9:293-297.
Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecular-weight heparins based on chemical, biological and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008;34:74-85.
25.
Jeske WP, Ackerman PD, Drenth A., Walenga J., Bakhos M.Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays. J Thromb Haemost.2007; 5(suppl 2):P-M-647.
26.
Jeske WP, Ma Q., Maddineni J., et al. Biochemical and pharmacologic equivalence of generic versions of low molecular weight heparins. A comparative study with innovator products . J Thromb Haemost.2005; 3(suppl 1):P1899.
